Flow Cytometry Findings of Aberrant Expression in a Cohort of Patients with Acute Myeloid Leukaemia

Main Article Content

C. C. Kariyawasan
B. L. T. Balasuriya
S. A. C. D. Ranatunga

Abstract

Background: Acute leukaemia is defined as the presence of over 20% of blasts cells in the blood or bone marrow. Acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) are the 2 main types. AMLs have characteristic morphological findings and molecular features with different surface and cytoplasmic cluster of differentiation (CD) markers. These CD markers are determined by immunophenotyping/flow cytometry on leukocytes which helps with accurate diagnosis and reproducibility of AMLs. Flow cytometry plays an important role in the diagnosis, sub classification and monitoring of patients with AML. AML generally shows aberrant CD expression or co- expression in relation to normal myeloid cells.

Objective of the Study: Objective of the Study was to evaluate the frequency and the pattern of aberrant CD expression in AML patients referred to a tertiary care hospital in Sri Lanka in comparison to other published data. There was no comparative data available in respect of Sri Lanka.

Materials and Methods: A retrospective descriptive study including 26 cases of AML diagnosed over a period of 12 months were analyzed. Diagnosis of AML was made by morphology of peripheral blood, bone marrow, trephine biopsies, Sudan Black B stain and the immunophenotypic analysis by multiparameter flow cytometry on bone marrow aspirates or peripheral blood. The markers used in flow cytometry were CD 45, CD34, CD19, CD7, smCD3, cyCD3, cyMPO, cyCD79a, CD20, CD15, CD10, CD5, HLADR, CD64, CD13, CD117, CD33, CD14.

Results: Among the 26 AML patients, 15 cases (57.69%) had the conventional CD antigen expressions of myeloid lineage. Other 11 cases (42.3%) were AML with aberrant expression of CD markers. Aberrancies of cyCD3 and CD7 were observed in 54.5% and 45.4% AML cases, respectively. smCD3 in 1 case out of 11 aberrant AML cases. Co expression of T lymphoid markers with myeloid markers occurred in 23% cases in our study. CD13 was not expressed in 1 case out of 5 AML- M4 cases and 1 case out of 7 AML- M1.  CD33 was not expressed in 1 case out of 2 AML -M0 cases.

Conclusion: We conclude that aberrant expression of CD markers is seen in a significant population of AMLs. cyCD 3, CD7 and smCD 3 were the aberrant markers present in our study population with cyCD3 showing highest frequency.

Keywords:
Leukocytes, flow cytometry findings, aberrant expression, acute myeloid Leukaemia.

Article Details

How to Cite
C. Kariyawasan, C., L. T. Balasuriya, B., & A. C. D. Ranatunga, S. (2020). Flow Cytometry Findings of Aberrant Expression in a Cohort of Patients with Acute Myeloid Leukaemia. Asian Hematology Research Journal, 2(4), 1-6. Retrieved from http://journalahrj.com/index.php/AHRJ/article/view/30117
Section
Short Research Article

References

Hoffbrand AV, Moss PAH. Hoffbrand’s essential haematology, John Wiley & Sons Ltd. 2010;06:178.

Azad AK, Khan MR, Habib ABMH, Begum M. Uncommon CD markers in acute myeloid leukaemia, Bangabandhu Sheikh Mujib Medical University Journal. 2018;11: 267-269.

Azad AK, Khan MR, Habib ABMH, Wadud MA, Begum M. Aberrent expression of CD markers in Acute Myeloid Leukaemia, Haematology Journal of Bangladesh. 2018;2(1):14-16.

Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F, Arcese W, Amadori S, Venditti A. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012;119: 332- 41.

Jha R, Grover G, Bose P, Lymphoid associated antigen expression in new cases of Acute Myeloid Leukaemia, Journal of Pathology of Nepal. 2013;3: 487-490.

Gorczyca W, Flow cytometry in neoplastic hematology morphologic–immune-pheno-typic correlation. 2nd ed. 2010;136-197.

Khalidi HS, Medeiros LJ, Chang KL, Brynes RK, Slovak ML, Arber DA .The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype. French-American-British classification and karyotypic abnormalities. American Journal of Clinical Pathology. 1998;109:211–20.

Zheng J, Wang X, Hu Y, et al. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China. Cytometry B Clinical Cytometry. 2008;74:25-9.

Bahia DM, Yamamoto M, Chauffaille Mde L et al. Aberrant phenotypes in acute myeloid leukemia: A highf requency and its clinical significance. Haematologica. 2001; 86:801-6.

Reading CL, Estey EH, Huh YO, et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood. 1993;81:3083–90.

Kita K, Miwa H, Nakase K, et al. Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/ Lymphoma. Blood. 1993;81:2399- 405.

Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4ed. 2017;179-181.

Khurram MM, Jafri SA, Mannan A, Nadeem A, Jamal A. Frequency of aberrant expression of CD markers in cases of acute leukemia. Medical Journal of Islamic World Academy of Science. 2010;18:55-60.